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P
rostate carcinoma (PC) is one of the most
commonly diagnosed carcinomas in the
world and is the second leading cause of can-
cer-related deaths in men (Boring et al., 1992).
This statistic has spurred greater interest in PC
research as a means to find posssible diagnostic
approaches and therapeutic interventions.
At the same time, PC is considered to be the most
frequently undiagnosed or under-diagnosed tumour
(Sakr et al., 1993). Over the past 20 years, the
overall survival rates for all stages of prostate can-
cer combined have increased from about 60% to
up to 97%, probably due to its early detection
(Giard et al., 1998,Tricoli et al. 2004). For patient
outcome prediction, it is important to establish the
grading of the carcinoma, which is done according
to Gleason’s system (GS), based on a low magnifi-
cation image of the cancerous gland (Gleason,
1966 and 1977). GS has two main advantages for
clinicians: i) it is easy to learn and apply, and ii) it
has been demonstrated to be correlated with the
prognosis (Kramer et al., 1980). Nevertheless,
there are some drawbacks: i) the grade may be
under- or overestimated when a minimal amount of
malignant cells are present in the biopsy, and ii) the
multifocality of the PC with a simultaneous variety
of differentiation may complicate the evaluation of
neoplastic gland size and shape. These problems
have been described as especially important to
identify grade 6, the most commonly diagnosed PC,
since, in the past, GS grades from 5 to 7 were con-
sidered to be intermediate grades of differentiation;
however, McNeal et al. (1990) and Epstein et al.
(1996) have reported that GS 7 may be more
aggressive than grades 5 or 6.
The spectrum of PC is additionally complicated
by the existence of prostatic intraepithelial neo-
plasm (PIN), a fundamental step during prostate
tumourigenesis (McNeal and Bostwick, 1986).
©2006, European Journal of Histochemistry
This review addresses the significance of the expression of
proliferating cell nuclear antigen (PCNA), p53 and some heat
shock proteins (Hsps) in prostate carcinoma (PC). In fact,
PCNA and p53 are two widely discussed tools in PC diagno-
sis, mainly because of the controversy regarding the signifi-
cance of their expression during prostate cancer development
and progression. At the same time, only few studies have
shown the potential role of Hsps in carcinogenesis and their
overexpression in pre-neoplastic and neoplastic lesions of the
prostate.We briefly describe the physiological roles of Hsps in
normal cells, and the significance of their immunohistochem-
ical detection in PC as well as in pre-cancerous lesions of the
prostate. We will also discuss the possible functional interac-
tions of these molecules in both dysplastic and neoplastic
cells.
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PINs are well recognised as being pre-malignant
(dysplastic) lesions of the prostate which were pre-
viously classified in three categories, depending on
the level of dysplasia: mild (PIN-1), moderate
(PIN-2) and severe (PIN-3). Nevertheless, more
recent clinical evidence has prompted pathologists
to further divide PINs into two groups, low- and
high-grade PIN (respectively L-PIN and H-PIN).
Although it has also been proposed to combine
PIN-1 and PIN-2 as L-PIN (Montironi et al.,
1990; Crissman et al., 1993; Jones and Young,
1994), it is now well recognised that PIN-2 and
PIN-3 should be considered as H-PIN (Drago et
al., 1989; Epstein et al., 1995).
Many researchers have hypothesised that the
tumour progression from L-PIN to invasive carci-
noma follows a predictable natural course
(Bostwick and Brawer, 1987; Brawer, 1992). On
the other hand, the molecular mechanisms at the
base of this progression have not been well eluci-
dated to date, although numerous papers have
shown the expression of several biological markers
during prostate carcinogenesis, identified their role
during carcinogenetic steps, and tested them as
diagnostic and prognostic tools (Sakr et al., 2000;
Alsikafi et al., 2001; Prange et al., 2001; Sakr and
Partin, 2001).
In this review, we speculate on the clinical value
of two well-known biological markers of carcino-
genesis, PCNA and p53, as well as some novel bio-
markers of PC progression, specifically Hsps, since
only recently has their overexpression been shown
in PC. Their role in normal cells and their possible
involvement in prostate carcinogenesis are briefly
described; finally, we postulate some possible
molecular interactions among some of these pro-
teins during the development and progression of
PC.
PCNA and p53 interactions in normal cells 
Proliferating cell nuclear antigen (PCNA) is a
eukaryotic protein involved in DNA repair, replica-
tion, post-replication modifications and chromatin
assembly. Active PCNA is a trimeric protein form-
ing a sliding clamp around DNA. In immunohisto-
chemical staining, PCNA is commonly found in G1-
and G2-phases of the cell cycle. PCNA interacts
with eukaryotic DNA polymerase to form a repli-
some. The interaction of cell cycle regulatory pro-
teins, which make up a part of the p53 response
pathway (i.e. p21 with PCNA), may be fundamen-
tal for cell survival, since it represents the link
between the DNA damage response and the regula-
tion of DNA replication and repair. When this
mechanism is disrupted, mutations accumulate,
genetic integrity is lost, and the cell cycle is dereg-
ulated (Jonsson and Hubscher, 1997).
p53 was first discovered and identified as a
tumour suppressor gene (Lane and Crawford,
1979); later it was found to participate in almost
all cell activities. The p53 tumour-suppressor pro-
tein controls the expression of the gene encoding
the p21-regulatory protein of cyclin-dependent
kinase. During p53-mediated suppression of cell
proliferation, p21 and PCNA are involved in coor-
dinating the repair of damaged DNA (Levine et al.,
1991) (Figure 1).
The p53 gene is frequently mutated in a number
of malignant human tumours (Oren, 1992;
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Figure 1. This scheme depicts the functional interaction
between p53 and PCNA. DNA damage induces the synthesis of
p53 which, in turn, determines p21 production and the arrest
of the cell cycle, with consequent inhibition of PCNA.
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Cappello et al., 2002a). In the case of DNA dam-
age, the abnormal p53 protein produced by a
mutant gene is ineffective (and often more stable)
than the wild-type protein; it becomes less sensitive
to proteolysis and tends to accumulate in the nucle-
us, being easily detected by classic immunohisto-
chemical techniques (Bruner et al., 1993).
Heat Shock Proteins in normal and tumour cells
Hsps (heat shock proteins), discovered over 40
years ago (Ritossa, 1962), comprise several highly
conserved families of functionally related proteins,
most of which are affiliated with the large and
diverse group of molecular chaperones that are
defined by their capacity to recognize and to bind
substrate proteins that are in an unstable or inac-
tive state (Ellis, 1990). Among them, Hsp60,
Hsp10 and Hsp90 are constitutively expressed in
mammalian cells, while Hsp27 and Hsp70 are com-
monly induced by stresses (Garrido et al., 2001).
Hsps have different functions inside normal cells,
such as prevention of the aggregation of denatured
polypeptides (Burel et al., 1992), interorganellar
transport (De Nagel and Pierce, 1991), and antigen
processing and presentation (Li et al., 1997).
Moreover, most Hsps have been proposed to regu-
late apoptosis. Hsp70, Hsp90 and Hsp27 are con-
sidered as antiapoptotic, since they bind to some
pro-apoptotic molecules, including cytochrome c
and Apaf (Li et al., 1997). In contrast, Hsp60 and
Hsp10 were firstly described as proapoptotic,
although this opinion has been recently capsized
(Gupta and Knowlton, 2005).
Hsp60 and Hsp10 are localized mostly in the
mitochondria of normal eukaryotic cells.They inter-
act in a two-step process of protein folding (Figure
2) (Richardson et al., 1998). Protein folding is
likely to occur within the cavity of cylindrical
Hsp60/Hsp10 complexes in a so-called infinite dilu-
tion cage where no intermolecular interactions
interfere with the folding process (Martin, 1997,
Bukau and Horwich, 1998).The Hsp60/10 machine
may also actively unfold kinetically-trapped inter-
mediates, which creates a second chance of proper
folding for the protein (Sigler et al., 1998; Voos
and Rottgers, 2002).The Hsp60/10 complex works
in an ATP-dependent manner: a single protein
undergoes multiple rounds of binding and is
released from the complex before it reaches the
final native state conformation (Bukau and
Horwich, 1998). Due to the physiologically low
amount of these Hsps in normal cells, research
using immunohistochemistry is sometimes not sen-
sitive enough, and more sophisticated techniques,
such as immunogold-staining, may be necessary to
study their cellular localisation in normal tissues
(Figure 3). By contrast, their expression may be
increased in a number of pathologic conditions,
such as tumour cell tranformation (Cappello et al.,
2002b; 2003a; 2003b).
Although Hsp60 and Hsp10 have been recog-
nised as key factors in protein folding within the
mitochondria, it has now become evident that sig-
nificant amounts of these chaperones may also be
found in extra-mitochondrial locations in normal
cells (Soltys and Gupta, 1996; Khan et al., 1998;
Sadacharan et al., 2001). Both extra-mitochondri-
al Hsp60 and Hsp10 have been proposed to act as
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Figure 2. HSP60 and HSP10 form a complex inside mitochon-
dria which acts in an ATP-mediated mechanism in protein fold-
ing.
Figure 3. Transmission immunoelectron microphotographs
showing intramitochondrial location of HSP60 (a) and HSP10
(b) in CHO cells. Higher magnifications show that only few mol-
ecules of HSP60 (a1) and HSP10 (b1) are present inside mito-
chondria.
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anti-apoptotic molecules (Samali et al., 1999;
Knowlton and Gupta, 2003), although the role of
the Hsp60/10 complex outside the mitochondria
has not been fully elucidated to date. It is possible
that the Hsp60/10 chaperone machine does not
operate as a single unit, but as a part of a cell sig-
nalling network in the cytoplasm (Dubaquie et al.,
1998). It has also been reported that some Hsps,
including Hsp60, Hsp70, and Hsp90 are capable of
inducing the production of proinflammatory
cytokines by the monocyte-macrophage system and
the activation and maturation of dendritic cells
(Tsan and Gao, 2004).
Involvement of Hsp60 and Hsp10 in the 
apoptotic pathway
Samali (1999) and Xanthoudakis (1999) were
the first to demonstrate an interaction of Hsp60
and pro-caspase 3 in the mitochondria of HeLa and
Jurkatt cells as well as the disruption of this com-
plex and the dissociation of p20 and p17 (active
caspase fragments) from Hsp60 with the simulta-
neous release of proteins (cytochrome c, adenylate
kinase) from the intermembranous space of mito-
chondria. These authors hypothesised that Hsp60,
due to its function as a 'foldase' chaperone, acceler-
ates caspase-3 maturation by folding pro-caspase 3
into a protease cleavage-favouring conformation
(Samali et al., 1999; Xanthoudakis et al., 1999).
On the other hand, Gupta and Knowlton (2005)
suggest that cytosolic Hsp60 could act as an anti-
apoptotic protein, since Hsp60 associated with
BAX sequester the latter away from the mitochon-
dria thus preventing the onset of apoptosis. When
the Hsp60 level was experimentally reduced, BAX
protein was found to be synthesized and bcl-2 pro-
tein to be degraded, which, in coherence with
translocation of BAX to mitochondria, contributed
to cytochrome c release and apoptosis progression
(Gupta and Knowlton, 2002; Kirchhoff et al.,
2002). In our studies, mutated p53 was only found
in advanced carcinomas; by contrast, Hsp60 and
Hsp10 overexpression was an early event in the
development of prostate cancer (Cappello et al.,
2003c; Cappello et al., 2003d). This leads us to
query the mechanisms that allow the cell to over-
come the cell cycle control in order to divide con-
tinuously despite the fact that the main tumour sup-
pressor gene is not mutated and should, therefore,
arrest the cell cycle and prohibit excessive prolifer-
ation. We postulate that this could be due to an
interaction between the Hsp60/10 machine and
p53, analogously to that already suggested for
Hsp70. In fact, it has already been demonstrated
that Hsp70 family members interact with the p53
C-terminal domain, playing a role in regulating the
equilibrium of p53 translocation between the
nuclear and cytoplasmic compartments (Wadhwa
et al., 1998; Wadhwa et al., 2002); analogously,
recently it has been proposed that other molecular
chaperones, such as Hsp70, could be involved in the
regulation of p53 localization (Zylicz et al., 2001).
In our opinion, the Hsp60/10 complex and p53
could also be considered in equilibrium for trigger-
ing apoptosis (Figure 4).
PCNA is currently the best marker in prostate can-
cer management
The differentiation and proliferative activity of
tumour cells are important predictors of the
aggressiveness of a carcinoma (Sakr et al., 1993;
Cher et al., 1995). PCNA-positive immunostaining
has been demonstrated to be related to the grade of
the carcinoma (Visakorpi, 1992a; McNeal et al.,
1995). In particular, it has been postulated that the
PCNA index can be used as an objective and quan-
titative means for evaluation of the malignancy of
PC (Nemoto et al., 1993; Naito et al., 1994;
Cappello et al., 2003c). Moreover, the evaluation of
the PCNA amount by immunohistochemistry may
be particularly useful in diagnosis based on small-
needle biopsies where the assessment of the grade
may be difficult because the available tumour tissue
is limited (Spires et al., 1994; Limas and Frizelle,
1994).
PCNA has also been found to be expressed in
PIN, supporting the hypothesis that these are pre-
neoplastic lesions (Myers and Grizzle, 1997). In
particular, research on PCNA has shown that pro-
liferative activity in H-PIN is increased when com-
pared to L-PIN and normal tissue (Myers and
Grizzle, 1996; Xie et al., 2000).The discovery that
PCNA in H-PIN has an intermediate expression
between that of a benign and carcinomatous
prostate also supports the claim that H-PIN is a
fundamental step in prostate carcinogenesis
(Tamboli et al., 1996). Moreover, a study on the
proliferation index for the peripheral and the tran-
sitional zone of the prostate showed a significant
difference, supporting the hypothesis of a biologic
difference between carcinomas arising in these dif-
ferent zones (Grignon and Sakr, 1994). PCNA may
help to predict prognosis, since the measurement of
PCNA immunolabeling provides important prog-
nostic information in T1-2 N0M0 tumours, in addi-
tion to the GS (Vesalainen et al., 1994). Indeed,
patients with a lower PCNA expression survive sig-
nificantly longer than those with a higher one
(Vesalainen et al., 1994). PCNA levels have also
been tested in post-radiotherapy prostate biopsies
by correlating their staining with the clinical out-
come, uncovering that PCNA negativity predicts an
eventual recovery from the tumour, while PCNA
positivity correlates with local failure (Crook et al.,
1994).
In the light of these data, PCNA immunostaining
should be considered to be one of the best indices of
PC behaviour. Although the proliferative activity
may be variable in PC, it also seems to be correlat-
ed with p53 overexpression; indeed, PCNA has a
significantly higher expression in tumours with p53-
positive cells (Van Veldhuizen et al., 1993; Kuczyk
et al., 1994; Leite et al., 1999; Al-Maghrabi et al.,
2001; Cappello et al., 2003d;). Consequently, p53
mutation could be an early event in at least a sub-
set of PCNA-positive PC (Cappello et al., 2003c).
The role of p53 mutation is still non-conclusive
Most authors believe that the mutation of the
p53 tumour suppressor gene typically occurs in
advanced stages of PC, but not in PINs (Navone et
al., 1993; Mottaz et al., 1997; Myers and Grizzle,
1997; Cappello et al., 2003d). Nevertheless, some
authors have found p53 immunopositivity in H-
PIN, with a pattern of expression similar to that
found in PC, but significantly different from benign
prostate neoplasms (Humphrey and Swanson,
1995;Tamboli et al., 1998).
Concerning PC development and progression,
many authors have demonstrated a correlation
between p53 immunoreactivity and high grade GS
(Kallakury et al., 1994; Myers et al., 1994), but
this datum is still under debate (Berner et al.,
1995; Dorkin et al., 1997; Karaburun et al.,
2001).The p53 expression has also been correlated
with both increased histologic grade and presence
of metastases, suggesting that p53 expression may
be linked to the tumour behaviour (Thomas et al.,
1993; Hughes et al., 1995; Sasor et al., 2000;
Karaburun et al., 2001). In particular, the p53
gene mutations seems to be associated with
advanced stages, presence of metastases, loss of
ability to differentiate, and transition from andro-
gen-dependent to androgen-independent growth
(Navone et al., 1993; Vesalainen et al., 1994;
Voeller et al., 1994; Brooks et al., 1996; Uzoaru et
al., 1998; Cheng et al., 1999). In contrast, some
authors have reported that p53 mutations are
infrequent in both primary and metastatic PC, and
they could not find a correlation between p53
mutation and tumour metastases (Dinjens et al.,
1994; Stattin et al., 1996). Other authors have
postulated that p53 reactivity could be an inde-
pendent prognostic indicator between low- and
intermediate-grade carcinomas (Shurbaji et al.,
1995; Bauer et al., 1995). The lower p53 expres-
sion in PC has also been related to a lower Gleason
score, as well as to a lower expression of other
markers of tumour growth and behaviour in both
transition and peripheral zones (Erbersdobler et
al., 2002), but these data were not confirmed
(Sulik and Guzinska-Ustymowicz, 2002).
Nevertheless, patients with negative p53 neoplastic
tissue obtained from a prostate biopsy are likely to
have a good prognosis in prolonged follow-up
(Bauer et al., 1995; Stattin et al., 1996;
Erbersdobler et al., 2002).
Concerning therapy, p53 abnormalities have been
associated with lymph node metastases derived
from PC patients who have not undergone hormon-
al treatment (Eastham et al., 1995). Apakama and
co-workers (1996) have proposed that the com-
bined detection of p53 and bcl-2 overexpression
predicts hormone resistance in PC. Also, an abnor-
mal p53 finding in early and hormone refractory
disease may be related to PC progression (Aprikian
et al., 1994; Henke et al., 1994; Heidenberg et al.,
1995; Koivisto and Rantala, 1999).The p53 status
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Figure 4. We hypothesise that the anti-apoptotic effects of the
HSP60/10 complex may antagonise the pro-apoptotic effect of
wild-type p53 during prostate cancer development.
could also help to circumscribe a group of patients
before radiotherapy, since p53 inactivation could
produce radio-resistant tumours (Stattin et al.,
1996). At the same time, in other studies, p53 pro-
tein overexpression was not predictive of outcome
in patients treated with radiation therapy
(Incognito et al., 2000). Another study showed that
the accumulation of p53 detected by immunohisto-
chemistry was an independent prognostic factor in
patients with PC during follow-up (Borre et al.,
2000).
In our opinion, the wide discrepancy of p53 muta-
tion in the reported studies may depend not only on
the type of tumour, but also on the region of the
tumour included in the study. Indeed, a heteroge-
neous topographical distribution of the mutant p53
has been observed, and analysis of the topographi-
cal distribution of the mutant p53 protein shows
remarkable differences (Mirchandani et al., 1995).
P53-positive nuclei have also been noted in basal
cells of benign glandular acini in regions flanking
the tumour, supporting the notion that the mutation
of p53 might play a role in the prostate carcino-
genesis (Kallakury et al., 1994). The mutation of
p53 has also been associated with increased angio-
genesis in PC (Yu et al., 1997) as well as with the
presence of post-atrophic hyperplasia, one of the
patterns of prostatic atrophy considered to be a
precursor of PC (Tsujimoto et al., 2002). Finally,
sarcomatoid carcinoma may develop from a high-
grade PC if associated with a progressive accumu-
lation of p53 (Delahunt et al., 1999).
In conclusion, while many studies have demon-
strated a strong relationship between p53 nuclear
positivity and disease-specific mortality, they seem
to be non-conclusive.We agree with Visakorpi et al.
(1992a; 1992b) who hypothesised that p53 accu-
mulation may confer a proliferative advantage for
PC cells and may define a small subgroup of highly
malignant carcinomas.
May Hsps detection help in the management of
prostatic cancer?
An increased expression of several Hsps has been
reported in a number of tumours (Mosser and
Morimoto, 2004; Ciocca and Calderwood, 2005).
Some Hsps were found to be over-expressed in
breast cancer, hepatomas and neuroectodermal
tumours (Soti and Csermely, 1998). In particular,
Hsp27 has been reported to be overexpressed in
breast (Ioachim et al., 2003) and endometrial
(Zagorianakou et al., 2003) carcinomas as well as
in leukemia (Kasimir-Bauer et al., 1998).
Increased expression of Hsp70 has been reported in
high-grade malignant tumours including breast,
endometrial, lung, pancreatic, renal, bone, colon
carcinoma and blood neoplasm (Soti and Csermely,
1998; Gaudin et al., 1999; Zylicz et al., 2001;
Moalic-Juge et al., 2002; Myung et al., 2004).
Hsp90 has been shown to be overexpressed in lung
(Zhong et al., 2003) and breast carcinomas
(Neckers, 2002). Overall, the high expression of
these Hsps have been associated with metastases,
poor prognosis and resistance to chemotherapy and
radiation therapy (Ciocca et al., 1993; Fuqua et al.,
1994; Vargas-Roig, 1998; Cornford et al., 2000).
We recently studied the expression of two Hsps in
some different carcinogenetic models, the dyspla-
sia-carcinoma sequence of the exocervix and colon
(Cappello et al., 2002b; 2003a; 2003b).This study
showed an accumulation of cytoplasmic Hsp60 and
Hsp10 in tumour cells and in the dysplastic ele-
ments, where they became easily detectable by
immunohistochemistry when compared to controls.
Such results have been confirmed by other studies
(Yang et al., 2004; Castle et al., 2005).
A number of papers have delved on the role of the
overexpression of several Hsps in prostate tumour
cells in vitro (Harvey et al., 2002; Sreedhar and
Csermely, 2004). Indeed, it has been postulated
that the overexpression of some Hsps, specifically
Hsp27, Hsp70 and Hsp72 could become targets for
multimodal anticancer treatments and for antitu-
moural immunity stimulation (Roigas et al., 2002;
Lipinski et al., 2005). Only a few studies concern
the expression of Hsps during prostate carcinogen-
esis in vivo. Hsp27 is one of the most studied Hsps
in PC. Storm et al., (1993) investigated the diag-
nostic and prognostic significance of Hsp27 in a
series of PCs, finding that the expression of this
molecule does not have any significance. In con-
trast, Cornford et al. (2000) demonstrated that
Hsp27 expression is an independent predictor of
clinical outcome for PC. An overexpression of
Hsp90 and Hsp60 has also been found in PC
(Alaiya et al., 2000). Since PCs are hormone-
dependent tumours that respond to drugs which
prevent binding of androgens to their receptors
(AR), and since AR exists in a complex with Hsp90,
it has been suggested that inhibitors of Hsp90 may
represent a novel strategy for the treatment of
patients with PC (Solit et al., 2003). However, clin-
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ical trials to test this hypothesis have yet to be com-
pleted.
We explored the expression of both Hsp60 and
Hsp10 during prostate carcinogenesis, finding an
early overexpression of these molecules. A high
cytoplasmic positivity for both of these markers
was present in PIN lesions as well as in carcino-
mas. Moreover, their overexpression was not corre-
lated with PCNA and p53 immunopositivity, since
PCNA grew from PIN to carcinoma and p53 muta-
tions were commonly reported as a late event
(Cappello et al., 2003d). Nevertheless, their prog-
nostic and therapeutic roles still need to be evalu-
ated.
Conclusions
The immunohistochemical evaluation of PCNA is
currently considered to be a very useful index of PC
behaviour. Since PCNA also has a significantly
higher expression in tumours with p53-positive
cells, the simultaneous validation of the expression
of both markers may serve as a useful tool in the
process of therapeutic strategy planning. By con-
trast, the significance of p53 status alone is still
doubtful, although the presence of its mutation may
help to make a prognosis. Finally, a few studies
have investigated the prognostic role of Hsps over-
expression and are as yet still inconclusive.
Nevertheless, the analysis of this body of literature
may allow us to postulate new hypotheses. Indeed,
since a number of papers reported a possible
involvement of Hsp60 and Hsp10 in the process of
apoptosis, it is tempting to suggest a possible link
between the Hsp60/10 machinery and the process
tumourigenesis. Indeed, although the expression of
Hsps should be a protective mechanism for stressed
cells, we support the thesis that their overexpres-
sion during carcinogenesis may influence cell
growth negatively and interfere with apoptotic
pathways. This hypothesis, if confirmed in vivo,
could help us to identify some Hsps, among which
is the Hsp60/10 complex, as a molecular target for
antitumoural therapies in multimodal treatment
approaches.
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